Biology's Code Rewritten: A New Blueprint for Resilient Therapeutics

CAMBRIDGE, England – June 25, 2026 – In a move that validates a fundamental shift in our ability to engineer biology, Professor Jason Chin has been named the 2026 recipient of the Heinrich Wieland Prize, one of Europe's most significant honors for life sciences research. The award recognizes his pioneering work in expanding the genetic code, a breakthrough that is not just redefining the boundaries of synthetic biology but is also powering a new engine for therapeutic innovation at his company, Constructive Bio.

This isn't merely an academic accolade; it's a marker of permanence for a technology poised to build more resilient and effective medicines. By learning to write new words into the language of life, Professor Chin has provided a blueprint for creating molecules that nature alone cannot, opening a direct path to a new generation of drugs, from next-generation GLP-1s to therapeutics previously deemed impossible to manufacture.

A Prize Reserved for Pioneers

The Heinrich Wieland Prize is a name that resonates with scientific legacy. Bestowed by the Boehringer Ingelheim Stiftung, it is an award reserved for those whose fundamental research has irrevocably altered our understanding of biochemistry, chemistry, and physiology. With a prize of 250,000 EUR, its significance is underscored by its list of past laureates, a veritable hall of fame that includes five scientists who later received the Nobel Prize: Michael Brown, Joseph Goldstein, Bengt Samuelsson, James Rothman, and Carolyn Bertozzi. Placing Professor Chin in this lineage is a powerful statement about the perceived impact of his contributions.

Established in 1963 and expanded in scope since 2011, the prize honors research that opens new frontiers. The selection by a board of internationally renowned scientists is a rigorous peer-review process that identifies work of exceptional originality and long-term significance. For Professor Chin, the award recognizes a career dedicated to asking a profound question: could the fixed rules of biology be systematically rewritten? His affirmative answer has become the foundation for a global field of research and, now, a commercial enterprise aimed at industrial-scale impact.

Unfreezing the Genetic Code

At the heart of this recognition is Professor Chin's success in achieving what was once a theoretical dream: the expansion of the genetic code. All natural life uses a 64-codon genetic code to build proteins from a set of 20 canonical amino acids. Chin's breakthrough was to engineer cells, specifically bacteria, with a rewritten, compressed genetic code. This freed up redundant codons, allowing them to be reassigned to entirely new, non-natural amino acids (ncAAs). In essence, he taught the cell's machinery to read new words and use new building blocks.

This is the core of what Sir Greg Winter, Chair of the Board of Constructive Bio, describes as Chin’s “long-term strategic vision… to unfreeze the genetic code.” This vision required the monumental task of synthesizing entire bacterial genomes to reassign codons, and then creating new cellular translation machinery to incorporate the unnatural amino acids. The result is a platform that allows for the biosynthesis of proteins and polymers with properties absent in nature—enhanced stability, novel functions, and improved therapeutic profiles. This methodology has since become the most widely adopted approach for creating non-natural proteins, a testament to its robustness and transformative power.

The Commercial Engine: Constructive Bio's Industrial Revolution

While the science is foundational, its translation into scalable, real-world applications is where its true performance is being tested. In 2022, Professor Chin founded Constructive Bio to do just that. The company is the commercial engine built upon his academic breakthroughs, applying the platform to pharmaceutical discovery and manufacturing. As CEO Ola Wlodek stated, “Jason’s work has fundamentally changed what biology can be asked to do. What began as a profound scientific question… has become the foundation for entirely new capabilities in drug discovery and manufacturing.”

The company's Syn61 bacterial strain is the workhorse of this new industrial biology. It enables the fermentation of products containing up to three different ncAAs at a multi-gram-per-litre scale. This is a critical milestone. Peptides that previously required complex and wasteful chemical synthesis can now be 'grown' through fermentation. This biological manufacturing process promises to be far more efficient, cost-effective, and environmentally sustainable.

The most immediate and compelling application is in the production of GLP-1 agonists, the class of drugs transforming the treatment of diabetes and obesity. Constructive Bio has already created a set of potent and DPPIV-resistant GLP-1 agonists. By incorporating ncAAs, the company can design these molecules to have superior properties, such as longer half-lives or improved stability, directly addressing the limitations of existing treatments. This is a clear demonstration of building a 'winner' in a highly competitive therapeutic landscape.

A New Paradigm for Drug Discovery

The implications of this technology extend far beyond optimizing existing drug classes. Sir Greg Winter draws a powerful parallel, suggesting these developments are reminiscent of “how the application of recombinant DNA technology led to the transformation of medicine and the pharmaceutical industry by therapeutic antibodies.” That transformation created entire new markets and treatment modalities. Genetic code expansion promises a similar paradigm shift, moving the industry from merely using biology's existing toolkit to designing a new one from the ground up.

By enabling the precise incorporation of novel chemical functionalities into proteins and peptides, Constructive Bio’s platform offers a rational, design-led approach to drug discovery. Scientists are no longer limited by the 20 amino acids provided by nature. They can now design molecules with specific, desired properties, opening the door to tackling diseases that have so far eluded conventional protein engineering. This represents a durable competitive advantage, building resilience and innovation directly into the manufacturing process.

Reflecting on the journey, Professor Chin himself captures the spirit of the endeavor. “We were motivated by a simple question: can the rules we thought were fixed in biology be systematically changed?” he said. “It is exciting to see these ideas now finding broader application in science, and increasingly in the development of useful new therapeutics and materials.”